SARS-CoV-2 variant mutations conferring reduced susceptibility to antiviral drugs and monoclonal antibodies: a non-systematic literature review for surveillance purposes

Antiviral drugs and monoclonal antibodies (mAbs), administered either separately or as combination therapy ‘cocktails’, have provided a valuable tool for fighting COVID-19. Surveillance data, coupled with data on antiviral treatment susceptibility, can guide clinical decisions on selecting the best therapy for the patient.